The combination of lovastatin and gefitinib effectively downregulates ras protein and suppresses the Raf, ERK1/2, AKT, and EGFR phosphorylation in gefitinib-resistant A549 and NCI-H460 human NSCLC cells [20]. Here, MAPK3 is linked to non-small cell lung carcinoma.